| scholarly article | Q13442814 |
| P50 | author | Brona M Murphy | Q58811046 |
| P2093 | author name string | Markus Rehm | |
| Birgit C Weyhenmeyer | |||
| Frank A Lincoln | |||
| Grainne Johnston | |||
| Janis Noonan | |||
| Maximilian L Würstle | |||
| P2860 | cites work | Temozolomide: mechanisms of action, repair and resistance | Q39436413 |
| Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells | Q39680489 | ||
| TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. | Q39753656 | ||
| Enhancement of tumor-TRAIL susceptibility by modulation of autophagy | Q39943681 | ||
| Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins | Q39956386 | ||
| Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma | Q40070342 | ||
| Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model | Q40508031 | ||
| Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. | Q40775835 | ||
| Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. | Q40975748 | ||
| Prognostic factors for glioblastoma patients--a clinical population-based study. | Q41377266 | ||
| Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein | Q41834899 | ||
| The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. | Q42064781 | ||
| The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma. | Q42968961 | ||
| The dark side of TRAIL signaling | Q43130518 | ||
| Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles | Q43218101 | ||
| Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide | Q43259949 | ||
| Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis | Q46448054 | ||
| Revisiting the role of p53 in primary and secondary glioblastomas | Q48314523 | ||
| Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo | Q48548442 | ||
| Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. | Q55035703 | ||
| Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. | Q55463299 | ||
| The Scree Test For The Number Of Factors | Q56210944 | ||
| Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function | Q24293924 | ||
| Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP | Q24302531 | ||
| Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors | Q24310559 | ||
| Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor | Q24597543 | ||
| Onto better TRAILs for cancer treatment | Q26768160 | ||
| The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond | Q26851645 | ||
| Small-molecule SMAC mimetics as new cancer therapeutics | Q26864204 | ||
| Getting TRAIL back on track for cancer therapy | Q27027460 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Quantitative and logic modelling of molecular and gene networks | Q28083248 | ||
| Apoptosis: controlled demolition at the cellular level | Q29620114 | ||
| Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells | Q30549646 | ||
| Imaging genomics of Glioblastoma: state of the art bridge between genomics and neuroradiology | Q30874551 | ||
| Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. | Q33245190 | ||
| Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme | Q33387317 | ||
| Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial | Q33401179 | ||
| Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial | Q33402747 | ||
| Tetravalent antibody-scTRAIL fusion proteins with improved properties | Q33619046 | ||
| BH3 mimetics: status of the field and new developments | Q34037924 | ||
| BH3-only proteins in apoptosis and beyond: an overview | Q34085370 | ||
| Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells | Q34321143 | ||
| Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme | Q34679133 | ||
| Cancer stem cells in glioblastoma | Q35829972 | ||
| On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics | Q35853714 | ||
| BH3-only proteins in apoptosis at a glance | Q35883875 | ||
| Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling. | Q35922585 | ||
| BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis | Q36152548 | ||
| Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme | Q36525099 | ||
| Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas | Q36651893 | ||
| Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment | Q36683578 | ||
| Mechanisms of disease: temozolomide and glioblastoma--look to the future | Q37187383 | ||
| Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial | Q37278379 | ||
| Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial | Q37325097 | ||
| Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide | Q37356520 | ||
| TRAIL on trial: preclinical advances in cancer therapy | Q37433463 | ||
| Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma | Q37585453 | ||
| Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis | Q37610475 | ||
| Cancer stem cells in glioma: challenges and opportunities | Q37634973 | ||
| Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics | Q37761935 | ||
| BH3-only proteins: Orchestrators of apoptosis | Q37819153 | ||
| Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases | Q37921609 | ||
| Cancer stem cell contribution to glioblastoma invasiveness | Q38091173 | ||
| Cellular mechanisms controlling caspase activation and function | Q38111614 | ||
| Glioblastoma multiforme: a look inside its heterogeneous nature | Q38182805 | ||
| MGMT testing--the challenges for biomarker-based glioma treatment | Q38218848 | ||
| Molecular heterogeneity of glioblastoma and its clinical relevance | Q38243193 | ||
| Cell death controlling complexes and their potential therapeutic role | Q38260863 | ||
| Biomarkers of glioblastoma multiforme | Q38281859 | ||
| Venetoclax: First Global Approval | Q38853500 | ||
| Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma. | Q38920339 | ||
| APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors | Q39084817 | ||
| Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment | Q39167592 | ||
| Systems analysis of BCL2 protein family interactions establishes a model to predict responses to chemotherapy. | Q39208647 | ||
| ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells | Q39236559 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 38 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell death | Q2383867 |
| temozolomide | Q425088 | ||
| P1104 | number of pages | 17 | |
| P304 | page(s) | 61295-61311 | |
| P577 | publication date | 2016-08-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide | |
| P478 | volume | 7 |
| Q55456993 | Bufalin induces apoptosis and improves the sensitivity of human glioma stem-like cells to temozolamide. |
| Q47648800 | Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition |
| Q38709582 | Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling |
| Q58547260 | Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism |
| Q64063271 | The combined efficacy of OTS964 and temozolomide for reducing the size of power-law coded heterogeneous glioma stem cell populations |
Search more.